- Sputnik International, 1920
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Russian Health Ministry Authorises Clinical Trials of EpiVacCorona-N Vaccine

© Sputnik / Evgeniy Odinokov / Go to the photo bankEvaluation of Sputnik V Vaccine Effectiveness at the Gemotest Laboratory in Moscow, Russia
Evaluation of Sputnik V Vaccine Effectiveness at the Gemotest Laboratory in Moscow, Russia - Sputnik International, 1920, 09.04.2021
Subscribe
International
India
MOSCOW (Sputnik) - The Russian Health Ministry has authorized phase 1 and 2 clinical trials of EpiVacCorona-N, one more coronavirus vaccine developed by the Vector research center, according to the ministry's register.

"An open study of the safety, tolerability, reactogenicity and immunising power of the EpiVacCorona-N peptide antigen-based vaccine for preventing COVID, involving volunteers aged 18-60 (phase 1-2)," the register read.

The trials started on April 8 and are set to end on September 30.

The EpiVacCorona vaccine, developed by the Vector State Research Centre of Virology and Biotechnology, is a peptide-based drug that relies on a promising synthetic platform. It consists of artificially synthesised short fragments of viral proteins - peptides, through which the immune system learns how to recognise and then neutralise the virus.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала